» Articles » PMID: 22752494

Friedreich Ataxia Clinical Outcome Measures: Natural History Evaluation in 410 Participants

Abstract

Friedreich ataxia is an autosomal recessive neurodegenerative disorder characterized by ataxia, dysarthria, and areflexia. The authors report the progress of a large international noninterventional cohort (n = 410), tracking the natural history of disease progression using the neurologic examination-based Friedreich Ataxia Rating Scale. The authors analyzed the rate of progression with cross-sectional analysis and longitudinal analysis over a 2-year period. The Friedreich Ataxia Rating Scale captured disease progression when used at 1 and 2 years following initial evaluation, with a lower ratio of standard deviation of change to mean change over 2 years of evaluation. However, modeling of disease progression identified substantial ceiling effects in the Friedreich Ataxia Rating Scale, suggesting this measure is most useful in subjects before maximal deficit is approached.

Citing Articles

NAD+ precursors prolong survival and improve cardiac phenotypes in a mouse model of Friedreich's Ataxia.

Perry C, Halawani S, Mukherjee S, Ngaba L, Lieu M, Lee W JCI Insight. 2024; 9(16).

PMID: 39171530 PMC: 11343603. DOI: 10.1172/jci.insight.177152.


CRPD frontiers in movement disorders Therapeutics: From evidence to treatment and applications: Addressing Patients' Needs in the Management of the Ataxias.

Perlman S Clin Park Relat Disord. 2024; 10:100255.

PMID: 38798918 PMC: 11126860. DOI: 10.1016/j.prdoa.2024.100255.


Retinal hypoplasia and degeneration result in vision loss in Friedreich ataxia.

Rodden L, McIntyre K, Keita M, Wells M, Park C, Profeta V Ann Clin Transl Neurol. 2023; 10(8):1397-1406.

PMID: 37334854 PMC: 10424660. DOI: 10.1002/acn3.51830.


Frataxin deficiency lowers lean mass and triggers the integrated stress response in skeletal muscle.

Vasquez-Trincado C, Dunn J, Han J, Hymms B, Tamaroff J, Patel M JCI Insight. 2022; 7(9).

PMID: 35531957 PMC: 9090249. DOI: 10.1172/jci.insight.155201.


Bone Mineral Density and Current Bone Health Screening Practices in Friedreich's Ataxia.

Dunn J, Tamaroff J, DeDio A, Nguyen S, Wade K, Cilenti N Front Neurosci. 2022; 16:818750.

PMID: 35368287 PMC: 8964400. DOI: 10.3389/fnins.2022.818750.


References
1.
Marelli C, Figoni J, Charles P, Anheim M, Tchikviladze M, Vincitorio C . Annual change in Friedreich's ataxia evaluated by the Scale for the Assessment and Rating of Ataxia (SARA) is independent of disease severity. Mov Disord. 2011; 27(1):135-8. DOI: 10.1002/mds.23879. View

2.
Fahey M, Corben L, Collins V, Churchyard A, Delatycki M . How is disease progress in Friedreich's ataxia best measured? A study of four rating scales. J Neurol Neurosurg Psychiatry. 2006; 78(4):411-3. PMC: 2077798. DOI: 10.1136/jnnp.2006.096008. View

3.
Regner S, Lagedrost S, Plappert T, Paulsen E, Friedman L, Snyder M . Analysis of echocardiograms in a large heterogeneous cohort of patients with friedreich ataxia. Am J Cardiol. 2011; 109(3):401-5. DOI: 10.1016/j.amjcard.2011.09.025. View

4.
Schols L, Zange J, Abele M, Schillings M, Skipka G, Kuntz-Hehner S . L-carnitine and creatine in Friedreich's ataxia. A randomized, placebo-controlled crossover trial. J Neural Transm (Vienna). 2004; 112(6):789-96. DOI: 10.1007/s00702-004-0216-x. View

5.
Lynch D, Farmer J, Balcer L, Wilson R . Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch Neurol. 2002; 59(5):743-7. DOI: 10.1001/archneur.59.5.743. View